Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Unicycive Therapeutics stock

Learn how to easily invest in Unicycive Therapeutics stock.

Unicycive Therapeutics Inc. is a biotechnology business based in the US. Unicycive Therapeutics shares (UNCY) are listed on the NASDAQ and all prices are listed in US Dollars. Unicycive Therapeutics employs 1 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Unicycive Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – UNCY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Unicycive Therapeutics stock price (NASDAQ: UNCY)

Use our graph to track the performance of UNCY stocks over time.

Unicycive Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$1.69
52-week range$1.68 - $8.73
50-day moving average $2.26
200-day moving average $2.63
Wall St. target price$13.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.81

Buy Unicycive Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Unicycive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Unicycive Therapeutics price performance over time

Historical closes compared with the close of $1.69 from 2022-01-21

1 week (2022-01-14) -5.59%
1 month (2021-12-23) -19.14%
3 months (2021-10-22) -33.46%
6 months (2021-07-23) -43.29%
1 year (2021-01-19) N/A
2 years (2020-01-19) N/A
3 years (2019-01-19) N/A
5 years (2017-01-19) N/A

Unicycive Therapeutics financials

Gross profit TTM $0
Return on assets TTM -43.39%
Return on equity TTM -95.06%
Profit margin 0%
Book value $1.27
Market capitalisation $26.8 million

TTM: trailing 12 months

Unicycive Therapeutics share dividends

We're not expecting Unicycive Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Unicycive Therapeutics overview

Unicycive Therapeutics, Inc. , a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. .

Frequently asked questions

What percentage of Unicycive Therapeutics is owned by insiders or institutions?
Currently 39.613% of Unicycive Therapeutics shares are held by insiders and 12.618% by institutions.
How many people work for Unicycive Therapeutics?
Latest data suggests 1 work at Unicycive Therapeutics.
When does the fiscal year end for Unicycive Therapeutics?
Unicycive Therapeutics's fiscal year ends in December.
Where is Unicycive Therapeutics based?
Unicycive Therapeutics's address is: 5150 El Camino Real, Los Altos, CA, United States, 94022
What is Unicycive Therapeutics's ISIN number?
Unicycive Therapeutics's international securities identification number is: US90466Y1038

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site